Back

Effects on mitral and tricuspid valve regurgitation after 6 months of treatment with SGLT2 inhibitors in patients with chronic heart failure

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pathophysiological mechanisms in heart failure: novel insights Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Paolo Basile

University of Bari, Bari (Italy)

7 More presentations in this session

Presentation thumbnail
Sympathetic vasoconstrictor constraint on exercise capacity in heart failure: does biological sex matter?
Doctor M. Badrov (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Relationship between pulmonary artery wedge pressure and left atrial pressure: pathophysiologic implications
Doctor A. Tada (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Predicting factors of right ventricular-pulmonary artery uncoupling assessed by TAPSE/PASP ratio after discharge in patients with heart failure and mildly reduced ejection fraction
Doctor M. Ono (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Temporal trend of hemodynamic functional indices in isolated PVAD and combined therapy with VA-ECMO
Doctor K. Teramoto (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Interventricular septum displacement and hemodynamic evaluation across heart failure spectrum during exercise performance
Doctor G. Crisci (Hasselt, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Pathophysiological mechanisms in heart failure: novel insights

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
Short-term effects of SGLT2 inhibitors on myocardial extracellular volume, left ventricular function and inflammation in patients with HFpEF and diabetes mellitus
thumbnail
Congress Presentation
Effects of SGLT-2 inhibitors on myocardial work in patients with heart failure with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources